Need your assistance, something seems off, perhaps you can shed some light.
Hard to tell exactly what is going on with Zander since we have not had any fins for 2 1/2 years, however I am not sure how they are getting .186168 per share?
NOTE 9. INVESTMENT SECURITIES, RELATED PARY
On June 11, 2018 Regen Biopharma, Inc. was paid a property dividend consisting of 470,588 of the common shares of Zander Therapeutics, Inc.
On November 29, 2018 the Company accepted 725,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. in satisfaction of prepaid rent and accrued interest owed to the Company collectively amounting to $13,124.
On June 30,2022 the Company revalued 470,588 of the common shares of Zander Therapeutics, Inc. and 725,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. based on the following inputs:
Fair Value of Intellectual Property $ 1,500
Prepaid Expenses 65,661
Due from Employee 1,071
Note Receivable 64,400
Accrued Interest Receivable 23,989
Investment Securities 8,423,366
Convertible Note Receivable 10,000
Accounts Payable 1,269,041
Notes Payable 400,000
Accrued Expenses Related Parties 162,011
Notes Payable Related Party 5396
Accrued Expenses 203,037
Enterprise Value 10,563,930
Less: Total Debt (2,038,343 )
Portion of Enterprise Value Attributable to Shareholders 8,525,587
Fair Value Per Share $ 0.186168
The abovementioned constitute the Company’s sole related party investment securities as of June 30, 2022
As of June 30, 2022:
470,588 Common Shares of Zander Therapeutics, Inc.
Basis Fair Value Total Unrealized
Gains Net Unrealized Gain or (Loss) realized during the quarter ended June 30,2022
$ 5,741 $ 87,608 $ 81,867 $ 79,749
725,000 Series M Preferred of Zander Therapeutics, Inc.
Basis Fair Value Total Unrealized Gain Net Unrealized Gain or (Loss) realized during the quarter ended June 30, 2022
$ $13,124 $ 134,971 $ 121,847 $ 122,861
News 
Market Data 
Discover 
